Capricor Therapeutics, Inc. (CAPR) Presents at 2026 MDA Clinical & Scientific Conference - Slideshow
B. Riley Securities Maintains Buy on Capricor Therapeutics, Raises Price Target to $63
Piper Sandler Reiterates Overweight on Capricor Therapeutics, Raises Price Target to $58
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $60 Price Target
Loading...